Trevena (TRVN) Announces Earnings Results
Trevena (NASDAQ:TRVN) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.07, Morningstar.com reports. The firm had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.00 million.
Shares of TRVN traded up $0.02 during trading on Friday, reaching $0.66. 1,959,155 shares of the company traded hands, compared to its average volume of 5,466,274. Trevena has a twelve month low of $0.55 and a twelve month high of $3.58. The stock has a market cap of $46.48 million, a PE ratio of -0.54 and a beta of 0.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.40 and a quick ratio of 3.40.
A number of brokerages have commented on TRVN. Zacks Investment Research raised shares of Trevena from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Thursday. HC Wainwright downgraded shares of Trevena from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $3.00 to $0.75 in a research note on Monday, November 5th. Needham & Company LLC downgraded shares of Trevena from a “buy” rating to a “hold” rating in a research note on Friday, October 12th. Jefferies Financial Group downgraded shares of Trevena from a “buy” rating to a “hold” rating and reduced their target price for the stock from $10.00 to $1.00 in a research note on Wednesday, October 10th. Finally, JMP Securities lifted their target price on shares of Trevena from $4.00 to $15.00 and gave the stock an “outperform” rating in a research note on Friday, October 12th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $5.42.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.
Featured Story: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.